VRXA

Veraxa Biotech AG - Post de-SPAC VRXA

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$1.58M total
UBS Group AG
$295.6K--
GEODE CAPITAL MANAGEMENT, LLC
$225.2K--
CSS LLC/IL
$176.6K--
LMR Partners LLP
$120.1K--
Magnetar Financial LLC
$116.4K--
ARISTEIA CAPITAL, L.L.C.
$115.7K--
Alberta Investment Management Corp
$96.5K--
AQR Arbitrage LLC
$72.6K--
Clear Street Group Inc.
$53.5K--
JPMORGAN CHASE & CO
$44.6K--
HRT FINANCIAL LP
$35.0K--
BNP PARIBAS FINANCIAL MARKETS
$27.9K--
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$21.5K--
WHITEBOX ADVISORS LLC
$21.4K--
Wealthspring Capital LLC
$20.4K--
Westchester Capital Management, LLC
$20.3K--
PICTON MAHONEY ASSET MANAGEMENT
$19.3K--
TENOR CAPITAL MANAGEMENT Co., L.P.
$16.5K--
Shaolin Capital Management LLC
$15.7K--
MMCAP International Inc. SPC
$13.8K--
Lineage Point Capital LP
$11.3K--
Hudson Bay Capital Management LP
$11.0K--
Yakira Capital Management, Inc.
$10.8K--
BERKLEY W R CORP
$6.6K--
Verition Fund Management LLC
$4.8K--
See all 30 institutional holders →
Reading the latest SEC filing…

Financial metrics will appear once SEC EDGAR data is ingested for this company.

Loading ratio trend…

VRXA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Veraxa Biotech AG - Post de-SPAC (VRXA): stock profile, AI score and financials

Veraxa Biotech AG - Post de-SPAC (VRXA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. VRXA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of VRXA by reported 13-F value include UBS Group AG, GEODE CAPITAL MANAGEMENT, CSS, based on the most recent SEC filings. VRXA trades on the Nasdaq exchange and files with the SEC under CIK 2079109. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VRXA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Veraxa Biotech AG - Post de-SPAC directly from SEC EDGAR.

SEC EDGAR: CIK 2079109 →